Lacosamide monotherapy in clinical practice: A retrospective chart review
| Autor: | V. Villanueva 1, B.G. Giráldez 2, M. Toledo 3, G.J. De Haan 4, E. Cumbo 5, A. Gambardella 6, 7, M. De Backer 8, L. Joeres 9, M. Brunnert 9, P. Dedeken 8, J. Serratosa 2 |
|---|---|
| Přispěvatelé: | UAM. Departamento de Medicina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Lacosamide focal seizures Clinical practice Epilepsy antiepileptic drug 0302 clinical medicine Acetamides 030212 general & internal medicine General Medicine Middle Aged clinical practice Europe partial-onset Clinical Practice Partial-onset Neurology Tolerability monotherapy Original Article Anticonvulsants Female medicine.symptom Antiepileptic drug Somnolence Partial medicine.drug Adult medicine.medical_specialty Adolescent Medicina Focal seizures 03 medical and health sciences Seizures Internal medicine Chart review partial medicine Humans partial‐onset Aged Retrospective Studies business.industry Original Articles Retention rate Monotherapy medicine.disease Confidence interval epilepsy Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | ACTA NEUROLOGICA SCANDINAVICA r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname Acta Neurologica Scandinavica Acta neurologica Scandinavica 138 (2018): 186–194. doi:10.1111/ane.12920 info:cnr-pdr/source/autori:V. Villanueva 1, B.G. Giráldez 2, M. Toledo 3, G.J. De Haan 4, E. Cumbo 5, A. Gambardella 6,7, M. De Backer 8, L. Joeres 9, M. Brunnert 9, P. Dedeken 8,10, J. Serratosa 2/titolo:Lacosamide monotherapy in clinical practice: A retrospective chart review/doi:10.1111%2Fane.12920/rivista:Acta neurologica Scandinavica/anno:2018/pagina_da:186/pagina_a:194/intervallo_pagine:186–194/volume:138 Biblos-e Archivo. Repositorio Institucional de la UAM |
| ISSN: | 0001-6314 |
| Popis: | Objective: To assess effectiveness and tolerability of first-line and conversion to lacosamide monotherapy for focal seizures. Materials and Methods: Retrospective, non-interventional chart review of lacosamide monotherapy patients aged ≥16 years in Europe. Outcomes included retention rate at observational point (OP) 3 (12 ± 3 months), seizure freedom rates at OP2 (6 ± 3 months) and OP3 and adverse drug reactions (ADRs). Results: A total of 439 patients were included (98 first-line and 341 conversion to monotherapy; 128 aged ≥65 years [25 first-line and 103 conversion to monotherapy]). First-line and conversion to monotherapy retention rates were 60.2% (59/98; 95% confidence interval [CI] 49.8%-70.0%) and 62.5% (213/341; 57.1%-67.6%), respectively. Kaplan-Meier estimates of 12-month retention rates were 81.2% and 91.4% for first-line and conversion to monotherapy, respectively. First-line and conversion to monotherapy retention rates in patients aged ≥65 years were 60.0% (38.7%-78.9%) and 68.9% (59.1%-77.7%), respectively. At OP2, 66.3% of first-line and 63.0% of conversion to monotherapy patients were seizure free. At OP3, 60.2% of first-line and 52.5% of conversion to monotherapy patients were seizure free. In the ≥65 years subgroup, seizure freedom rates at OP2 were 72.0% and 68.0% for first-line and converted to monotherapy, respectively, and at OP3, 68.0% and 56.3%, respectively. Overall, 52 of 439 (11.8%) patients reported ADRs (16.4% in ≥65 years subgroup), most commonly dizziness (5.0%), headache (2.1%) and somnolence (1.6%). Conclusions: Lacosamide was effective and well tolerated as first-line or conversion to monotherapy in a clinical setting in adult and elderly patients with focal seizures This study was supported by UCB Pharma |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |